Nivolumab (new indication: esophageal squamous cell carcinoma, PD-L1-expression ≥ 1%, 1st line in combination with platinum- and fluoropyrimidine-based chemotherapy)


  • Active Substance: Nivolumab
  • Name: Opdivo®
  • Therapeutic area: Squamous cell carcinoma of the esophagus
  • Pharmaceutical company: Bristol-Myers Squibb GmbH & Co. KGaA

Time table:

  • Start: 01.05.2022
  • Final decision by G-BA: 20.10.2022

Final decision:

  • Indication for a considerable additional benefit